| Rachael A Callcut, MD | |
|
2315 Stockton Blvd, Naob, Suite 5006, Sacramento, CA 95817-2201 | |
| (650) 723-0173 | |
| Not Available |
| Full Name | Rachael A Callcut |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 23 Years |
| Location | 2315 Stockton Blvd, Sacramento, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023066677 | NPI | - | NPPES |
| 2000915630 | Medicaid | IN | |
| 7100058450 | Medicaid | KY | |
| 2905397 | Medicaid | OH |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of California Davis Medical Center | Sacramento, CA | Hospital |
| Adventist Health And Rideout | Marysville, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The Univ Of Ca | 3375456619 | 1346 |
News Archive
PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.
A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.
Cognitive neuroscientists Rosie Cowell and David Huber at the University of Massachusetts Amherst recently received a four-year, $2.36 million grant from the National Institutes of Health to develop a new computational tool that will help researchers in interpreting functional magnetic resonance images of the brain and improve accuracy in relating fMRI data to neural responses in the brain.
Synexus has created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus where it has delivered in excess of three thousand randomised patients in all three areas.
Researchers from Charité - Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications.
› Verified 1 days ago
| Entity Name | Regents Of The Univ Of Ca |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013906973 PECOS PAC ID: 3375456619 Enrollment ID: O20031111000892 |
News Archive
PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.
A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.
Cognitive neuroscientists Rosie Cowell and David Huber at the University of Massachusetts Amherst recently received a four-year, $2.36 million grant from the National Institutes of Health to develop a new computational tool that will help researchers in interpreting functional magnetic resonance images of the brain and improve accuracy in relating fMRI data to neural responses in the brain.
Synexus has created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus where it has delivered in excess of three thousand randomised patients in all three areas.
Researchers from Charité - Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications.
› Verified 1 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366417420 PECOS PAC ID: 5496668410 Enrollment ID: O20031112000551 |
News Archive
PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.
A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.
Cognitive neuroscientists Rosie Cowell and David Huber at the University of Massachusetts Amherst recently received a four-year, $2.36 million grant from the National Institutes of Health to develop a new computational tool that will help researchers in interpreting functional magnetic resonance images of the brain and improve accuracy in relating fMRI data to neural responses in the brain.
Synexus has created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus where it has delivered in excess of three thousand randomised patients in all three areas.
Researchers from Charité - Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications.
› Verified 1 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477528503 PECOS PAC ID: 5496668410 Enrollment ID: O20050328001092 |
News Archive
PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.
A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.
Cognitive neuroscientists Rosie Cowell and David Huber at the University of Massachusetts Amherst recently received a four-year, $2.36 million grant from the National Institutes of Health to develop a new computational tool that will help researchers in interpreting functional magnetic resonance images of the brain and improve accuracy in relating fMRI data to neural responses in the brain.
Synexus has created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus where it has delivered in excess of three thousand randomised patients in all three areas.
Researchers from Charité - Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachael A Callcut, MD 2315 Stockton Blvd, Naob, Suite 5006, Sacramento, CA 95817-2201 Ph: () - | Rachael A Callcut, MD 2315 Stockton Blvd, Naob, Suite 5006, Sacramento, CA 95817-2201 Ph: (650) 723-0173 |
News Archive
PsiOxus Therapeutics, Ltd., a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.
A protein abundantly found in treatment-resistant cancers holds an important tumor-suppressor out of the cell nucleus, where it would normally detect DNA damage and force defective cells to kill themselves, a team of scientists reports in the current Cancer Cell.
Cognitive neuroscientists Rosie Cowell and David Huber at the University of Massachusetts Amherst recently received a four-year, $2.36 million grant from the National Institutes of Health to develop a new computational tool that will help researchers in interpreting functional magnetic resonance images of the brain and improve accuracy in relating fMRI data to neural responses in the brain.
Synexus has created a specialist vaccines team to help pharma and biotech companies find the thousands of patients they need for their late phase trials. The company has a well-established reputation for delivering results in the vaccine field following successes in late phase vaccine trials including most recently, studies for cancer prevention, influenza and rotavirus where it has delivered in excess of three thousand randomised patients in all three areas.
Researchers from Charité - Universitätsmedizin Berlin and the Zuse Institute Berlin have developed a new generation of pain medications.
› Verified 1 days ago
Dr. Vijay P Khatri, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 4501 X St, Uc Davis Cancer Center, Suite 3010, Sacramento, CA 95817 Phone: 916-734-2172 Fax: 916-731-5706 | |
Dr. Rebecca Anne Stark, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2521 Stockton Blvd, Ucdmc Glassrock Peds. Surgery - Suite 3200, Sacramento, CA 95817 Phone: 916-734-3229 | |
Virginia R Barton, MD Surgery Medicare: Medicare Enrolled Practice Location: 3301 C St Ste 1400, Sacramento, CA 95816 Phone: 916-734-4457 | |
Dr. Garth Utter, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 2315 Stockton Blvd. - Department Of Surgery, Naob 5th Floor - Trauma, Sacramento, CA 95817 Phone: 916-734-1768 Fax: 916-734-7821 | |
Dr. Diana L. Farmer, MD Surgery Medicare: Medicare Enrolled Practice Location: 2221 Stockton Blvd., Cypress #3112, Sacramento, CA 95817 Phone: 916-734-3190 Fax: 916-734-5119 | |
Dr. Matthew Malcolm Pier, MD Surgery Medicare: Medicare Enrolled Practice Location: 4150 V Street, Pssb 1200, Sacramento, CA 95817 Phone: 916-734-5026 |